Walleye Capital LLC Allogene Therapeutics, Inc. Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $158,257 - $242,938	69,411 New	69,411 $222,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $52,534 - $78,163	11,597 Added 11.21%	115,032 $571,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $508,900 - $849,201	103,435 New	103,435 $510,000
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $535,435 - $743,458	-16,536 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $304,097 - $893,605	16,536 New	16,536 $708,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $233M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.